Evaluation of the frequency and intensity of favipiravir-associated yellow-green fluorescence in lunulae, hair, and face
© 2021 Wiley Periodicals LLC..
BACKGROUND: We detected yellow-green fluorescence in the face, hair and lunulae of patients using favipiravir.
AIM: We evaluated the frequency and intensity of favipiravir-associated fluorescence.
PATIENTS/METHODS: The participants comprised patients who had taken at least a single dose of favipiravir and been examined no later than 30 days after the last dose. The gender, age, body mass index (BMI), Fitzpatrick's skin-type, hair color, N-acetylcysteine use, presence and the intensity of fluorescent reflection under Wood's light in the lunulae of the fingernails, hair, and the face were recorded.
RESULTS: There were 275 patients, 144 (52.4%) of whom were women. 165 (57.9%) had used treatment for a maximum of 5 days, 99 (34.7%) for 6-10 days, and 21 (7.4%) for more than ten days. Using more than 22 tablets of favipiravir increased the probability of detecting fluorescence in the lunulae by 6.72 (2.61-17.23) times. Using more than 28 tablets increased the risk of fluorescence in hair and the T-zone by 5.92 (2.43-14.71) and 2.88 (1.11-7.47) times, respectively. No relationship was found between the fluorescence intensity in any localization and the total dose. However, we determined a negative correlation between the elapsed time after the last dose and the fluorescence intensity in the lunulae and the T-zone (p=0.036; p=0.031; respectively). It was noted that BMI negatively correlated with the fluorescence intensity in the lunulae (p=0.001). Skin type was related to intensity for all localizations (p<0.001). Fluorescence was found in the lunulae with significantly less frequency in patients using N-acetylcysteine (p=0.040).
CONCLUSIONS: We must be aware of favipiravir-induced phototoxicity.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
Journal of cosmetic dermatology - 21(2022), 3 vom: 01. März, Seite 1199-1207 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Turan, Çağrı [VerfasserIn] |
---|
Links: |
---|
Themen: |
Amides |
---|
Anmerkungen: |
Date Completed 28.02.2022 Date Revised 28.02.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/jocd.14189 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM324682735 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM324682735 | ||
003 | DE-627 | ||
005 | 20231225190834.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/jocd.14189 |2 doi | |
028 | 5 | 2 | |a pubmed24n1082.xml |
035 | |a (DE-627)NLM324682735 | ||
035 | |a (NLM)33915020 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Turan, Çağrı |e verfasserin |4 aut | |
245 | 1 | 0 | |a Evaluation of the frequency and intensity of favipiravir-associated yellow-green fluorescence in lunulae, hair, and face |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.02.2022 | ||
500 | |a Date Revised 28.02.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 Wiley Periodicals LLC. | ||
520 | |a BACKGROUND: We detected yellow-green fluorescence in the face, hair and lunulae of patients using favipiravir | ||
520 | |a AIM: We evaluated the frequency and intensity of favipiravir-associated fluorescence | ||
520 | |a PATIENTS/METHODS: The participants comprised patients who had taken at least a single dose of favipiravir and been examined no later than 30 days after the last dose. The gender, age, body mass index (BMI), Fitzpatrick's skin-type, hair color, N-acetylcysteine use, presence and the intensity of fluorescent reflection under Wood's light in the lunulae of the fingernails, hair, and the face were recorded | ||
520 | |a RESULTS: There were 275 patients, 144 (52.4%) of whom were women. 165 (57.9%) had used treatment for a maximum of 5 days, 99 (34.7%) for 6-10 days, and 21 (7.4%) for more than ten days. Using more than 22 tablets of favipiravir increased the probability of detecting fluorescence in the lunulae by 6.72 (2.61-17.23) times. Using more than 28 tablets increased the risk of fluorescence in hair and the T-zone by 5.92 (2.43-14.71) and 2.88 (1.11-7.47) times, respectively. No relationship was found between the fluorescence intensity in any localization and the total dose. However, we determined a negative correlation between the elapsed time after the last dose and the fluorescence intensity in the lunulae and the T-zone (p=0.036; p=0.031; respectively). It was noted that BMI negatively correlated with the fluorescence intensity in the lunulae (p=0.001). Skin type was related to intensity for all localizations (p<0.001). Fluorescence was found in the lunulae with significantly less frequency in patients using N-acetylcysteine (p=0.040) | ||
520 | |a CONCLUSIONS: We must be aware of favipiravir-induced phototoxicity | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a N-acetylcysteine | |
650 | 4 | |a favipiravir | |
650 | 4 | |a photosensitivity | |
650 | 4 | |a ultraviolet imaging | |
650 | 4 | |a wood'light | |
650 | 7 | |a Amides |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Pyrazines |2 NLM | |
650 | 7 | |a favipiravir |2 NLM | |
650 | 7 | |a EW5GL2X7E0 |2 NLM | |
700 | 1 | |a Metin, Nurcan |e verfasserin |4 aut | |
700 | 1 | |a Utlu, Zeynep |e verfasserin |4 aut | |
700 | 1 | |a Yıldız, Türkan Tuğba |e verfasserin |4 aut | |
700 | 1 | |a Caferoğlu Sakat, Selcen |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of cosmetic dermatology |d 2002 |g 21(2022), 3 vom: 01. März, Seite 1199-1207 |w (DE-627)NLM166816639 |x 1473-2165 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2022 |g number:3 |g day:01 |g month:03 |g pages:1199-1207 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/jocd.14189 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2022 |e 3 |b 01 |c 03 |h 1199-1207 |